The European Medicines Agency has approved the use of Celgene's Revlimid, or lenalidomide, in some myelodysplastic syndromes patients. The approval covers the use of the drug in patients with low- or intermediate-1-risk myelodysplastic syndrome and deletion 5q chromosomal abnormalities but no other chromo­somal ab­nor­mali­ties and who have become dependent on red blood cell transfusions and are not responding to other treatments.

Full Story:

Related Summaries